Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1802 2ND-STEP second-line treatment trial in advanced soft tissue sarcoma
jRCTs031190152Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS) comparing Trabectedin arm, Eribulin arm and Pazopanib arm (3 arms). Primary endpoint: progression-free survival. Started Dec 2019; status: completed.
02
Drugs
trabectedineribulinpazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs031190152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190152.